medline.ch Urologie-Nephrologie Tumoren BPH

	Evaluating Xerostomia as a side effect of [(255)Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging Al-Ibraheem A, Moghrabi S, Sathekge MM, Abdlkadir AS. PMID: 39984745 [PubMed - as supplied by publisher]
	Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. PMID: 39984485 [PubMed - indexed for MEDLINE]
	The Landscape of Supportive Care Needs Among Prostate Cancer Patients in New Zealand: A Cross-Ethnic Analysis. Psychooncology Xiao H, Baxter GD, Liu L, Hoeta T, Wibowo E. PMID: 39984302 [PubMed - indexed for MEDLINE]
	Assessing the Diagnostic Metrics of Cutaneous Leiomyomas in Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome: an Observational Study. J Am Acad Dermatol Ouchene L, Udupa M, Mija LA, Moussa S, Chergui M, Watters KA, Cruz-Marino T, Tanguay S, Brimo F, Fu L, Rahme E, Kaouache M, Foulkes WD, Netchiporouk E. PMID: 39984057 [PubMed - as supplied by publisher]
	Editorial Comment on "A comparison between intravesical Gemcitabine plus Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes". Urology Tripathy R, Kumar L. PMID: 39983790 [PubMed - as supplied by publisher]
	LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer. BMC Cancer Wen Y, Zhan S, Wang S, Yang L, Yang S, Zheng S. PMID: 39984881 [PubMed - as supplied by publisher]
	Integrating radiomics and gene expression by mapping on the image with improved DeepInsight for clear cell renal cell carcinoma. Cancer Genet Kawahara D, Kishi M, Kadooka Y, Hirose K, Murakami Y. PMID: 39983665 [PubMed - as supplied by publisher]
	Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10Â years. Int Urol Nephrol Fan H, Chen W, Guo W, Han J, Xie H, Yu Y, Ding G, Chen Y. PMID: 39982659 [PubMed - as supplied by publisher]
	[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]. Strahlenther Onkol Shelan M, Mathier E, Aebersold DM, Wiegel T. PMID: 39982503 [PubMed - as supplied by publisher]
	[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer]. Urologie Willner L, Tauber R, Eiber M. PMID: 39982466 [PubMed - as supplied by publisher]
	Multiparametric MRI before and after Focal Therapy for Prostate Cancer: Pearls and Pitfalls for the Reporting Radiologist. Radiol Imaging Cancer Lai AL, Velaga J, Tay KJ, Hang G, Tan YG, Yuen JSP, Cheng CWS, Ngo NT, Law YM. PMID: 39982208 [PubMed - indexed for MEDLINE]
	Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review). Oncol Rep Guo X, Li S. PMID: 39981932 [PubMed - indexed for MEDLINE]
	Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs. Front Immunol Li W, Luo P, Chen Q, Cheng L, Gan L, Zhang F, Zhong H, Zheng L, Qian B. PMID: 39981244 [PubMed - indexed for MEDLINE]
	Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom. BJUI Compass Rokan N, Reddy D. PMID: 39980983 [PubMed]
	Identification of hub genes, non-coding RNAs and pathways in Renal cell carcinoma (RCC): A comprehensive in silico study. Biochem Biophys Rep Golestanifar A, Khedri H, Noorabadi P, Saberiyan M. PMID: 39980583 [PubMed]
	Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single-Institution Pilot Study. Prostate Britton CJ, Andrews JR, Arafa A, Kim Y, Latuche LR, Schulte PJ, Joshi VB, Ahmed ME, Jeffrey Karnes R, Lucien F. PMID: 39980247 [PubMed - as supplied by publisher]
	A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients. Cancer Med Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale MG, Pipitone S, Baldessari C, Costantini M, Eccher A, Mastrolia I, Catani V, Bacchelli F, Ferretti S, Dominici M, Sabbatini R. PMID: 39980141 [PubMed - indexed for MEDLINE]
	GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis. BMC Urol Plage H, Frericks A, Hofbauer S, Furlano K, Weinberger S, Roßner F, Schallenberg S, Elezkurtaj S, Lennartz M, Marx A, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Koch S, Simon R, Sauter G, Zecha H, Weischenfeldt J, Klatte T, Minner S, Horst D, Schlomm T, Kluth M. PMID: 39979991 [PubMed - indexed for MEDLINE]
	Ectopic prostate tissue presenting as a bladder tumor in a young man- a case report. BMC Urol Akça G, Öztürk Ç, Uzun H. PMID: 39979876 [PubMed - indexed for MEDLINE]
	Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer. BMC Cancer Zheng Z, Dai F, Liu J, Zhang Y, Wang Z, Wang B, Qiu X. PMID: 39979837 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 174302

Seite 1 von 8716



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung